Elias Badal Rashu

Medicine & Life Sciences

1. Non-alcoholic Fatty Liver Disease 100%
2. Cholesterol Ester Storage Disease 80%
3. LCZ 696 72%
4. Glucagon 71%
5. Neprilysin 58%
6. Fatty Liver 55%
7. Type 2 Diabetes Mellitus 46%
8. Liver Diseases 44%
9. Glucose 38%
10. Liver Cirrhosis 36%
11. Referral and Consultation 32%
12. Liver 31%
13. Liver Transplantation 27%
14. Fibrosis 25%
15. Meals 21%
16. C-Peptide 19%
17. Sitagliptin Phosphate 19%
18. fibroblast growth factor 21 18%
19. Veins 16%
20. Glucagon-Like Peptide 1 15%
21. Siblings 13%
22. Pancreatic Hormones 13%
23. Amino Acids 12%
24. Dipeptidyl-Peptidase IV Inhibitors 11%
25. Biopsy 10%
26. Sterol Esterase 10%
27. Fasting 10%
28. Heart Failure 9%
29. Enzyme Replacement Therapy 9%
30. Gastrointestinal Diseases 7%
31. Base Pairing 7%
32. Insulin 7%
33. Dyslipidemias 7%
34. Hydroxymethylglutaryl-CoA Reductase Inhibitors 7%
35. Rare Diseases 7%
36. Hyperinsulinism 7%
37. Inborn Genetic Diseases 6%
38. Glucose Intolerance 6%
39. Single Nucleotide Polymorphism 6%
40. Exons 6%
41. Valsartan 6%
42. Cohort Studies 6%
43. Disease Progression 5%
44. Reference Values 5%
45. Physiological Feedback 5%
46. Regression Analysis 5%
47. Logistic Models 5%
48. Fats 5%
49. Cardiovascular Diseases 5%
50. Glucagon Receptors 5%